XOMA Royalty (NASDAQ:XOMA) Hits New 12-Month High – Should You Buy?

XOMA Royalty Corporation (NASDAQ:XOMA)’s stock price hit a new 52-week high on Thursday . The company traded as high as $43.00 and last traded at $42.9850, with a volume of 71958 shares. The stock had previously closed at $42.62.

Wall Street Analyst Weigh In

XOMA has been the topic of a number of recent analyst reports. Benchmark downgraded XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Friday, May 22nd. Weiss Ratings upgraded shares of XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 29th. Zacks Research upgraded shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. HC Wainwright downgraded XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price target on the stock. in a research report on Thursday, April 30th. Finally, Lucid Cap Mkts cut XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. One research analyst has rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $53.75.

XOMA Royalty Price Performance

The firm has a market cap of $539.22 million, a P/E ratio of 27.39 and a beta of 0.86. The stock’s 50-day moving average is $41.55 and its 200-day moving average is $32.81. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.96.

XOMA Royalty (NASDAQ:XOMA) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). The company had revenue of $12.32 million during the quarter, compared to the consensus estimate of $13.91 million. XOMA Royalty had a net margin of 53.46% and a return on equity of 12.56%. As a group, equities analysts anticipate that XOMA Royalty Corporation will post 0.9 EPS for the current fiscal year.

Institutional Investors Weigh In On XOMA Royalty

Several hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its position in XOMA Royalty by 207.7% during the first quarter. Dimensional Fund Advisors LP now owns 133,360 shares of the biotechnology company’s stock worth $4,182,000 after buying an additional 90,025 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in XOMA Royalty by 9.7% in the 1st quarter. Bank of New York Mellon Corp now owns 74,984 shares of the biotechnology company’s stock valued at $2,352,000 after acquiring an additional 6,600 shares in the last quarter. Opaleye Management Inc. raised its holdings in XOMA Royalty by 14.7% in the 4th quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock valued at $7,780,000 after acquiring an additional 37,503 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of XOMA Royalty in the 4th quarter worth approximately $237,000. Finally, Panagora Asset Management Inc. lifted its position in shares of XOMA Royalty by 24.2% in the 4th quarter. Panagora Asset Management Inc. now owns 21,229 shares of the biotechnology company’s stock worth $564,000 after acquiring an additional 4,135 shares during the period. Institutional investors own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.